On June 23, 2025, Bayzed Health Group Inc (“Bayzed Health”, 02609.HK) was officially listed on the Main Board of the Hong Kong Stock Exchange. The offering was priced at HK$4.22 per share, with approximately 133 million shares offered globally, raising total proceeds of around HK$562 million.

Bayzed Health is an oncology healthcare group that principally engages in the investment in, and provision of, medical and healthcare related services in the PRC. It operates and manages eight hospitals, offering full-cycle oncology healthcare services covering cancer screening and early detection, oncology diagnosis, treatment, and rehabilitation.

In this transaction, Eric Chow & Co. in Association with Commerce & Finance Law Offices, Edwin Kwok & Co, Commerce & Finance Law Offices, and Beijing Yingke Law Firm Hefei Office advised the issuer on matters relating to Hong Kong law, U.S. law, PRC law, and PRC law with respect to ongoing litigation related to contractual disputes, respectively. O’Melveny & Myers and Jingtian & Gongcheng acted as legal counsel to the sole sponsor and underwriters, advising on Hong Kong and U.S. law, and PRC law, respectively.